Psoriasis and Mortality in the US: Data from the National Health and Nutrition Examination Survey.

[1]  Jonathan H. Chung,et al.  Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study , 2019, Cardiovascular research.

[2]  M. Lai,et al.  All-Cause and Cause-Specific Mortality in Patients with Psoriasis in Taiwan: A Nationwide Population-Based Study. , 2017, The Journal of investigative dermatology.

[3]  S. Preston,et al.  Deaths Attributable to Diabetes in the United States: Comparison of Data Sources and Estimation Approaches , 2017, PloS one.

[4]  J. Silverberg,et al.  Serious infections in hospitalized patients with psoriasis in the United States. , 2016, Journal of the American Academy of Dermatology.

[5]  Zheng-Sheng Yang,et al.  The Effect of TNF Inhibitors on Cardiovascular Events in Psoriasis and Psoriatic Arthritis: an Updated Meta-Analysis , 2016, Clinical Reviews in Allergy & Immunology.

[6]  Daniel B. Shin,et al.  The Risk of Cancer in Patients With Psoriasis: A Population-Based Cohort Study in the Health Improvement Network. , 2016, JAMA dermatology.

[7]  Yang Zhao,et al.  Evaluating the economic burden of psoriasis in the United States. , 2015, Journal of the American Academy of Dermatology.

[8]  C. Torp-Pedersen,et al.  Nationwide population‐based study of cause‐specific death rates in patients with psoriasis , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  D. Margolis,et al.  Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study , 2014, Annals of the rheumatic diseases.

[10]  A. Armstrong,et al.  Psoriasis prevalence among adults in the United States. , 2014, Journal of the American Academy of Dermatology.

[11]  L. Puig,et al.  Predictors of biologic treatment of psoriasis: a non-interventional study , 2014, ClinicoEconomics and outcomes research : CEOR.

[12]  M. Lebwohl,et al.  Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. , 2013, JAMA dermatology.

[13]  M. Raftery,et al.  IL-29 Is Produced by TH17 Cells and Mediates the Cutaneous Antiviral Competence in Psoriasis , 2013, Science Translational Medicine.

[14]  L. Misery,et al.  Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[15]  A. Ogdie,et al.  Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study , 2012, Annals of the rheumatic diseases.

[16]  T. Nijsten,et al.  Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort. , 2011, Journal of the American Academy of Dermatology.

[17]  L. Skov,et al.  Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study , 2011, Journal of Internal Medicine.

[18]  A. Troxel,et al.  Cause‐specific mortality in patients with severe psoriasis: a population‐based cohort study in the U.K. , 2010, The British journal of dermatology.

[19]  J. Avorn,et al.  Immunosuppressants, mortality, and risk of cancer , 2009, BMJ : British Medical Journal.

[20]  J. Gelfand,et al.  The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. , 2009, Journal of the American Academy of Dermatology.

[21]  J. Dreiher,et al.  Psoriasis and chronic obstructive pulmonary disease: a case–control study , 2008, The British journal of dermatology.

[22]  K. Hyrich,et al.  International guidelines on access to biologic therapy: why the differences and which is best? , 2008, Nature Clinical Practice Rheumatology.

[23]  Andrea B Troxel,et al.  The risk of mortality in patients with psoriasis: results from a population-based study. , 2007, Archives of dermatology.

[24]  V. Shavers.  Measurement of socioeconomic status in health disparities research. , 2007, Journal of the National Medical Association.

[25]  L. Puig-Sanz.  La psoriasis, ¿una enfermedad sistémica? , 2007 .

[26]  Daniel B. Shin,et al.  The risk of lymphoma in patients with psoriasis. , 2006, The Journal of investigative dermatology.

[27]  M. Furukawa,et al.  Prices and availability of biopharmaceuticals: an international comparison. , 2006, Health affairs.

[28]  David J Margolis,et al.  Determinants of quality of life in patients with psoriasis: a study from the US population. , 2004, Journal of the American Academy of Dermatology.

[29]  David J Margolis,et al.  Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. , 2004, The journal of investigative dermatology. Symposium proceedings.

[30]  F. Granath,et al.  Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients , 2003, European Journal of Epidemiology.

[31]  P. Boffetta,et al.  Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. , 2001, The Journal of investigative dermatology.

[32]  M. Lebwohl,et al.  The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. , 2001, Archives of dermatology.

[33]  J. Koo.  Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. , 1996, Dermatologic clinics.

[34]  H. Yen,et al.  All‐cause and cause‐specific mortality in psoriasis: A systematic review and meta‐analysis , 2019, Journal of the American Academy of Dermatology.

[35]  J. Gelfand,et al.  Objective Measures of Psoriasis Severity Predict Mortality: A Prospective Population-Based Cohort Study. , 2018, The Journal of investigative dermatology.

[36]  J. Cappelleri,et al.  Increased cause-specific mortality in patients with mild and severe psoriasis: a population-based Swedish register study. , 2015, Acta dermato-venereologica.

[37]  C. Ryan,et al.  Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. , 2015, Dermatologic clinics.